Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.
about
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic TargetingCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyNovel technologies and emerging biomarkers for personalized cancer immunotherapyCTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their InhibitionIntegrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of ImmunotherapyCo-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?Control of CD8 T-Cell Infiltration into Tumors by Vasculature and MicroenvironmentValidation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validationSynthetic Nanoparticles for Vaccines and ImmunotherapyFacilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 BlockadeGenetic basis for clinical response to CTLA-4 blockade in melanoma3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire dataSynergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells.Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.Longitudinal analysis of peripheral blood T cell receptor diversity in patients with systemic lupus erythematosus by next-generation sequencingPeripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma.Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.Multiplex Identification of Antigen-Specific T Cell Receptors Using a Combination of Immune Assays and Immune Receptor SequencingVDJtools: Unifying Post-analysis of T Cell Receptor Repertoires.Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistanceAssociation of CD8(+) T lymphocyte repertoire spreading with the severity of DRESS syndrome.Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.Glycogen synthase kinase-3: a potential preventive target for prostate cancer managementImmunological correlates of treatment and response in stage IV malignant melanoma patients treated with IpilimumabDiversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination.Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank.Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire.What does PD-L1 positive or negative mean?TCRβ repertoire of CD4+ and CD8+ T cells is distinct in richness, distribution, and CDR3 amino acid composition.Kupfer-type immunological synapses in vivo: Raison D'être of SMAC.Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.Sequencing the functional antibody repertoire--diagnostic and therapeutic discovery.T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.
P2860
Q26742012-D479AE43-E5E0-490F-931D-8FD3715DD88FQ26745516-68BC31BC-8F88-4138-88EE-3E9AE17FC50CQ26770780-954D78AA-3D32-4876-ADC9-FB5DE25D444CQ26777563-6614907C-2943-436E-8443-4C53F77B3D8EQ26783783-B58248A9-E5B8-4302-A268-301AEA11589EQ26796099-0CDECC05-C661-47C6-A75C-D05E6A99D062Q26799117-B51B3D9F-E441-492D-9DE4-F257A4B4E116Q28075719-5CB5A096-FB6A-45C6-A669-C7CCDF6F1A00Q28085375-E9152FC9-15E0-4437-998B-1CD9C6657A84Q28119095-ABF98D1D-682C-44CF-8B9D-76BC7F31FF98Q29620594-95A51F27-F296-44C8-BE52-5636924350DEQ31167209-40C9EAB9-43F1-4609-9A84-B9D7BFA60185Q33591468-5D76FF16-EEA0-41D4-B8D0-B4725F133143Q33699687-0A68416B-FA5B-4672-BDBB-CDBB95832D8CQ34458339-4FE415A0-5435-4918-9F1D-B1EF0FF36712Q35221540-9BA5E9FA-3BBC-414C-925C-4E5D7550CBF7Q35463514-C9BB47A6-8C55-420E-91C6-70DB8ADDBA27Q35689999-4C4CDAE5-3492-4ED9-A42C-22FF5B2C5D89Q35748121-A2351E8C-5750-4432-9D74-F05034D2867AQ35751259-D55B9084-806F-4F9E-9ECE-B91BE914931BQ35824191-E506C8EA-1A58-40C6-9FF0-BE7B69499132Q35852353-7BF15827-D3AA-45F2-9908-C847314838F9Q36125878-0F2E03C6-1950-424A-BBE0-F48D01D85EE1Q36292362-00828ED7-902E-4D6E-AD24-5215FFD4E501Q36383913-83436DED-021D-4DC6-B0C0-AD344E483FCAQ36580561-4743F4DA-CC6B-4281-B1DF-CF10A8944685Q36821143-D55CB406-9D0D-4484-8398-07476D544640Q36931965-AA1BF134-91E4-4D0D-A8DB-8A9101358057Q37053881-D58AF819-E787-44AB-8FF1-F8CD5D859D24Q37340661-B6AB3C94-437B-4817-9FB2-8A802A2A703AQ37369239-73632E62-1448-4450-B809-6834CE2852E1Q37437334-F4F1649F-1901-4D75-AE3F-2427DADEE2F3Q37500381-EDBAF7B2-7705-4C9B-83EA-DA79B74AD5BFQ37682074-EB7131C9-DACF-4A20-B969-B62A2B2C510EQ38255424-F0920B0A-0739-4FEB-99AB-7C858839C8C5Q38259896-B6268205-4BD7-405D-A19D-680F5913FED6Q38264014-4ED9582E-93F9-48E0-AF90-82107C6F9E58Q38299138-2BAC848E-1460-40EC-93CB-728C2B973ABFQ38376433-858C3DA0-EA4F-43AD-B30C-CC160EEA277EQ38391533-78C267C3-4DA9-4945-8E5F-48E9DC2C2B2F
P2860
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Improved survival with T cell ...... treatment in cancer patients.
@ast
Improved survival with T cell ...... treatment in cancer patients.
@en
type
label
Improved survival with T cell ...... treatment in cancer patients.
@ast
Improved survival with T cell ...... treatment in cancer patients.
@en
prefLabel
Improved survival with T cell ...... treatment in cancer patients.
@ast
Improved survival with T cell ...... treatment in cancer patients.
@en
P2093
P2860
P1476
Improved survival with T cell ...... treatment in cancer patients.
@en
P2093
Antoni Ribas
Craig Cummings
Edward Cha
Lawrence Fong
Malek Faham
Mark Klinger
P2860
P304
P356
10.1126/SCITRANSLMED.3008211
P407
P577
2014-05-01T00:00:00Z